Understanding the Role of Nitric Oxide in Glaucoma Management

0.50 CME
0.50 CME WITH ABO Continuing Certification
30 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Understanding the Role of Nitric Oxide in Glaucoma Management

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Bausch + Lomb.


Activity Description

Glaucoma is a leading cause of blindness worldwide, with an estimated 80 million people living with this condition as of 2020. Many individuals with glaucoma remain at risk for disease progression due to inadequate control of intraocular pressure (IOP) with traditional medical options. Recent studies have demonstrated that nitric oxide (NO) signaling plays a key role in IOP regulation via its action on the conventional outflow pathway, and NO-donating agents produce significant functional improvements in this pathway. In this educational program, experts in the field discuss the role of NO in IOP reduction, and review clinical studies assessing NO-donating therapies in the treatment of glaucoma. Clinical case discussion will provide further guidance for the integration of NO-donating therapies into practice.


Target Audience

The intended audience for this activity is comprehensive ophthalmologists and other health care professionals involved in the management of patients with glaucoma.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate the rationale for using nitric oxide as a target in glaucoma management and the mechanisms by which it regulates intraocular pressure.
  • Assess the latest clinical evidence regarding the safety and efficacy of nitric oxide–based agents in glaucoma management.

Activity Chair

Thomas W. Samuelson, MD
Attending Surgeon
Glaucoma and Anterior Segment Surgery
Minnesota Eye Consultants, P.A.
Adjunct Professor of Ophthalmology
University of Minnesota
Minneapolis, MN


Faculty

Jason Bacharach, MD
Founding Partner and Director of Clinical Research
North Bay Eye Associates, Inc.
Co-Director, Glaucoma Division
California Pacific Medical Center
San Francisco, CA

Sarah H. Van Tassel, MD
New York, NY


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, July 16, 2021, to July 15, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Jason Bacharach, MD
Consulting Fee: Allergan, Bausch + Lomb, Santen
Speakers Bureau: Allergan, Bausch + Lomb
Contracted Research: Nicox

Thomas W. Samuelson, MD
Consulting Fee: Aerie, Alcon, Allergan, Bausch + Lomb/Valeant, BELKIN Laser, ELT Sight, Equinox, Glaukos, Imprimis, Ivantis, J&J Vision, Ocuphire, MicroOptx, New World Medical, PolyActiva, Ripple Therapeutics, Santen, Sight Science, TearClear, ViaLase, Zeiss
Ownership Interest: BELKIN Laser, Equinox, Ivantis, Ocuphire, Sight Science, TearClear, ViaLase

Sarah H. Van Tassel, MD
Consulting Fee: Allergan, Equinox, New World Medical

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com